Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated startle

Yi Ling Yang, Ya Wen Su, Ming Chong Ng, Po Kuan Chao, Li Chu Tung, Kwok-Tung Lu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A standard extract of Ginkgo biloba (EGb761) has been used in the treatment of various common geriatric complaints including vertigo, short-term memory loss, hearing loss, lack of attention, or vigilance. We demonstrated that acute systemic administration of EGb761 facilitated the acquisition of conditioned fear. Many studies suggest the neural mechanism underlies extinction is similar to the acquisition. This raises a possibility that EGb761 may modulate and accelerate the fear extinction process. We tested this possibility by using fear-potentiated startle (FPS) on laboratory rats. Acute systemic injection of EGb761 (10, 20, or 50 mg/kg) 30 min before extinction training facilitated extinction in a dose-dependent manner. Intra-amygdaloid infusion of EGb761 (28 ng/side, bilaterally) 10 min before extinction training also facilitated extinction. Control experiments showed that facilitation effect of EGb761 was not the result of impaired expression of conditioned fear or accelerated forgetting. Rats previously injected with EGb761 showed significant FPS after retraining. Extinction of conditioned fear appeared to result from acute drug effects rather than from toxic action. Systemic administration of EGb761 immediately after extinction training did not facilitate extinction, suggested the EGb761 facilitation effect is contributed to the acquisition phase of extinction learning. Western blot results showed that extinction induced amygdaloid extracellular signal-regulated kinase (ERK1/2) phosphorylation was significantly elevated by EGb761 treatment. Intra-amygdala injection of ERK1/2 inhibitor PD98059 completely blocked the EGb761 effect. Therefore, acute EGb761 administration modulated extinction of conditioned fear by activating ERK1/2.

Original languageEnglish
Pages (from-to)332-342
Number of pages11
JournalNeuropsychopharmacology
Volume32
Issue number2
DOIs
Publication statusPublished - 2007 Feb 1

Fingerprint

Ginkgo biloba
Fear
Psychological Extinction
Ginkgo biloba extract 761
Toxic Actions
Injections
Mitogen-Activated Protein Kinase 1
Vertigo
Memory Disorders
Amygdala
Short-Term Memory
Hearing Loss
Geriatrics

Keywords

  • EGb761
  • Extinction
  • Extracellular signal-regulated kinase
  • Fear-potentiated fear
  • Ginkgo biloba

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated startle. / Yang, Yi Ling; Su, Ya Wen; Ng, Ming Chong; Chao, Po Kuan; Tung, Li Chu; Lu, Kwok-Tung.

In: Neuropsychopharmacology, Vol. 32, No. 2, 01.02.2007, p. 332-342.

Research output: Contribution to journalArticle

Yang, Yi Ling ; Su, Ya Wen ; Ng, Ming Chong ; Chao, Po Kuan ; Tung, Li Chu ; Lu, Kwok-Tung. / Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated startle. In: Neuropsychopharmacology. 2007 ; Vol. 32, No. 2. pp. 332-342.
@article{944516cebda345e5a587d4a9f46eb1e1,
title = "Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated startle",
abstract = "A standard extract of Ginkgo biloba (EGb761) has been used in the treatment of various common geriatric complaints including vertigo, short-term memory loss, hearing loss, lack of attention, or vigilance. We demonstrated that acute systemic administration of EGb761 facilitated the acquisition of conditioned fear. Many studies suggest the neural mechanism underlies extinction is similar to the acquisition. This raises a possibility that EGb761 may modulate and accelerate the fear extinction process. We tested this possibility by using fear-potentiated startle (FPS) on laboratory rats. Acute systemic injection of EGb761 (10, 20, or 50 mg/kg) 30 min before extinction training facilitated extinction in a dose-dependent manner. Intra-amygdaloid infusion of EGb761 (28 ng/side, bilaterally) 10 min before extinction training also facilitated extinction. Control experiments showed that facilitation effect of EGb761 was not the result of impaired expression of conditioned fear or accelerated forgetting. Rats previously injected with EGb761 showed significant FPS after retraining. Extinction of conditioned fear appeared to result from acute drug effects rather than from toxic action. Systemic administration of EGb761 immediately after extinction training did not facilitate extinction, suggested the EGb761 facilitation effect is contributed to the acquisition phase of extinction learning. Western blot results showed that extinction induced amygdaloid extracellular signal-regulated kinase (ERK1/2) phosphorylation was significantly elevated by EGb761 treatment. Intra-amygdala injection of ERK1/2 inhibitor PD98059 completely blocked the EGb761 effect. Therefore, acute EGb761 administration modulated extinction of conditioned fear by activating ERK1/2.",
keywords = "EGb761, Extinction, Extracellular signal-regulated kinase, Fear-potentiated fear, Ginkgo biloba",
author = "Yang, {Yi Ling} and Su, {Ya Wen} and Ng, {Ming Chong} and Chao, {Po Kuan} and Tung, {Li Chu} and Kwok-Tung Lu",
year = "2007",
month = "2",
day = "1",
doi = "10.1038/sj.npp.1301060",
language = "English",
volume = "32",
pages = "332--342",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated startle

AU - Yang, Yi Ling

AU - Su, Ya Wen

AU - Ng, Ming Chong

AU - Chao, Po Kuan

AU - Tung, Li Chu

AU - Lu, Kwok-Tung

PY - 2007/2/1

Y1 - 2007/2/1

N2 - A standard extract of Ginkgo biloba (EGb761) has been used in the treatment of various common geriatric complaints including vertigo, short-term memory loss, hearing loss, lack of attention, or vigilance. We demonstrated that acute systemic administration of EGb761 facilitated the acquisition of conditioned fear. Many studies suggest the neural mechanism underlies extinction is similar to the acquisition. This raises a possibility that EGb761 may modulate and accelerate the fear extinction process. We tested this possibility by using fear-potentiated startle (FPS) on laboratory rats. Acute systemic injection of EGb761 (10, 20, or 50 mg/kg) 30 min before extinction training facilitated extinction in a dose-dependent manner. Intra-amygdaloid infusion of EGb761 (28 ng/side, bilaterally) 10 min before extinction training also facilitated extinction. Control experiments showed that facilitation effect of EGb761 was not the result of impaired expression of conditioned fear or accelerated forgetting. Rats previously injected with EGb761 showed significant FPS after retraining. Extinction of conditioned fear appeared to result from acute drug effects rather than from toxic action. Systemic administration of EGb761 immediately after extinction training did not facilitate extinction, suggested the EGb761 facilitation effect is contributed to the acquisition phase of extinction learning. Western blot results showed that extinction induced amygdaloid extracellular signal-regulated kinase (ERK1/2) phosphorylation was significantly elevated by EGb761 treatment. Intra-amygdala injection of ERK1/2 inhibitor PD98059 completely blocked the EGb761 effect. Therefore, acute EGb761 administration modulated extinction of conditioned fear by activating ERK1/2.

AB - A standard extract of Ginkgo biloba (EGb761) has been used in the treatment of various common geriatric complaints including vertigo, short-term memory loss, hearing loss, lack of attention, or vigilance. We demonstrated that acute systemic administration of EGb761 facilitated the acquisition of conditioned fear. Many studies suggest the neural mechanism underlies extinction is similar to the acquisition. This raises a possibility that EGb761 may modulate and accelerate the fear extinction process. We tested this possibility by using fear-potentiated startle (FPS) on laboratory rats. Acute systemic injection of EGb761 (10, 20, or 50 mg/kg) 30 min before extinction training facilitated extinction in a dose-dependent manner. Intra-amygdaloid infusion of EGb761 (28 ng/side, bilaterally) 10 min before extinction training also facilitated extinction. Control experiments showed that facilitation effect of EGb761 was not the result of impaired expression of conditioned fear or accelerated forgetting. Rats previously injected with EGb761 showed significant FPS after retraining. Extinction of conditioned fear appeared to result from acute drug effects rather than from toxic action. Systemic administration of EGb761 immediately after extinction training did not facilitate extinction, suggested the EGb761 facilitation effect is contributed to the acquisition phase of extinction learning. Western blot results showed that extinction induced amygdaloid extracellular signal-regulated kinase (ERK1/2) phosphorylation was significantly elevated by EGb761 treatment. Intra-amygdala injection of ERK1/2 inhibitor PD98059 completely blocked the EGb761 effect. Therefore, acute EGb761 administration modulated extinction of conditioned fear by activating ERK1/2.

KW - EGb761

KW - Extinction

KW - Extracellular signal-regulated kinase

KW - Fear-potentiated fear

KW - Ginkgo biloba

UR - http://www.scopus.com/inward/record.url?scp=33846261988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846261988&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301060

DO - 10.1038/sj.npp.1301060

M3 - Article

C2 - 16554745

AN - SCOPUS:33846261988

VL - 32

SP - 332

EP - 342

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -